Guo‐Feng Luo

5.1k total citations · 1 hit paper
74 papers, 4.5k citations indexed

About

Guo‐Feng Luo is a scholar working on Biomedical Engineering, Molecular Biology and Biomaterials. According to data from OpenAlex, Guo‐Feng Luo has authored 74 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Biomedical Engineering, 32 papers in Molecular Biology and 28 papers in Biomaterials. Recurrent topics in Guo‐Feng Luo's work include Nanoplatforms for cancer theranostics (36 papers), Nanoparticle-Based Drug Delivery (25 papers) and Advanced biosensing and bioanalysis techniques (23 papers). Guo‐Feng Luo is often cited by papers focused on Nanoplatforms for cancer theranostics (36 papers), Nanoparticle-Based Drug Delivery (25 papers) and Advanced biosensing and bioanalysis techniques (23 papers). Guo‐Feng Luo collaborates with scholars based in China, Israel and Maldives. Guo‐Feng Luo's co-authors include Xian‐Zheng Zhang, Wei‐Hai Chen, Ren‐Xi Zhuo, Qi Lei, Si‐Xue Cheng, Wen‐Xiu Qiu, Sheng Hong, Huizhen Jia, Li‐Han Liu and Xuan Zeng and has published in prestigious journals such as Journal of the American Chemical Society, Chemical Society Reviews and Advanced Materials.

In The Last Decade

Guo‐Feng Luo

70 papers receiving 4.5k citations

Hit Papers

Multifunctional Envelope-Type Mesoporous Silica Nanoparti... 2013 2026 2017 2021 2013 100 200 300 400

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Guo‐Feng Luo China 35 2.7k 1.9k 1.6k 1.4k 356 74 4.5k
Xinjian Yang China 39 2.5k 0.9× 1.0k 0.5× 2.0k 1.2× 1.7k 1.2× 218 0.6× 98 4.9k
Yuanzeng Min China 28 2.0k 0.7× 1.5k 0.8× 1.3k 0.8× 1.1k 0.8× 346 1.0× 61 4.0k
Han Cheng China 37 2.1k 0.8× 1.4k 0.7× 1.2k 0.7× 1.4k 1.0× 332 0.9× 109 4.2k
Changhui Fu China 39 3.3k 1.2× 1.7k 0.9× 1.0k 0.6× 2.3k 1.6× 347 1.0× 124 5.3k
Jingjing Liu China 31 3.4k 1.2× 1.3k 0.7× 1.4k 0.9× 2.3k 1.7× 562 1.6× 114 5.6k
Qingshuo Meng China 24 2.3k 0.9× 1.7k 0.9× 1.3k 0.8× 1.0k 0.7× 259 0.7× 35 3.6k
Yiye Li China 30 2.3k 0.9× 1.3k 0.6× 1.4k 0.9× 1.6k 1.2× 335 0.9× 50 4.3k
Jingyi Zhu China 39 2.3k 0.8× 1.8k 0.9× 1.8k 1.1× 1.0k 0.7× 354 1.0× 104 4.4k
Yu Luo China 36 3.3k 1.2× 1.9k 1.0× 1.0k 0.6× 1.5k 1.1× 442 1.2× 104 4.7k
Xuan Zeng China 50 3.2k 1.2× 1.5k 0.8× 1.7k 1.0× 3.2k 2.3× 488 1.4× 146 7.3k

Countries citing papers authored by Guo‐Feng Luo

Since Specialization
Citations

This map shows the geographic impact of Guo‐Feng Luo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guo‐Feng Luo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guo‐Feng Luo more than expected).

Fields of papers citing papers by Guo‐Feng Luo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guo‐Feng Luo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guo‐Feng Luo. The network helps show where Guo‐Feng Luo may publish in the future.

Co-authorship network of co-authors of Guo‐Feng Luo

This figure shows the co-authorship network connecting the top 25 collaborators of Guo‐Feng Luo. A scholar is included among the top collaborators of Guo‐Feng Luo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guo‐Feng Luo. Guo‐Feng Luo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chen, Ziyi, et al.. (2025). Nanomedicine for targeting cancer-associated fibroblasts in cancer therapy. Theranostics. 16(3). 1545–1576.
4.
Liu, Hanzhe, Zhi Liu, Tong Wang, et al.. (2024). Tea leaf-derived nanovesicles for ferric-supply-amplified ICD and macrophage reprogramming to boost immunotherapy against head and neck squamous carcinoma. Chemical Engineering Journal. 503. 158469–158469. 3 indexed citations
5.
Luo, Guo‐Feng, et al.. (2024). Modulators targeting protein-protein interactions in Mycobacterium tuberculosis. Microbiological Research. 284. 127675–127675. 5 indexed citations
7.
Luo, Guo‐Feng & Xian‐Zheng Zhang. (2024). Magnetic nanoparticles for use in bioimaging. Biomaterials Science. 12(24). 6224–6236. 2 indexed citations
8.
Jin, Lisheng, et al.. (2024). Multi-modality trajectory prediction with the dynamic spatial interaction among vehicles under connected vehicle environment. Scientific Reports. 14(1). 2873–2873. 7 indexed citations
9.
Luo, Guo‐Feng, Wei‐Hai Chen, & Xian‐Zheng Zhang. (2023). Nanomedicine Disrupts Stromal Barriers to Augment Drug Penetration for Improved Cancer Therapy. Chinese Journal of Chemistry. 42(10). 1175–1189. 4 indexed citations
10.
Liu, Hanzhe, Guo‐Feng Luo, & Z. J. Shang. (2023). Plant-derived nanovesicles as an emerging platform for cancer therapy. Acta Pharmaceutica Sinica B. 14(1). 133–154. 22 indexed citations
11.
Yang, Juan & Guo‐Feng Luo. (2023). Peptide-Based Vectors for Gene Delivery. Chemistry. 5(3). 1696–1718. 8 indexed citations
12.
Liang, Jun‐Long, Mei‐Ting Niu, Guo‐Feng Luo, et al.. (2022). Tailor-made biotuner against colorectal tumor microenvironment to transfer harms into treasures for synergistic oncotherapy. Nano Today. 47. 101662–101662. 12 indexed citations
13.
Luo, Guo‐Feng, Jun‐Long Liang, Diwei Zheng, et al.. (2022). Inhibiting Stress‐Activated Signals to Reverse Heat Resistance for Augmented Photothermal Therapy Based on Biologically Derived Nanotherapeutics. Advanced Functional Materials. 32(36). 14 indexed citations
14.
Liang, Jun‐Long, Guo‐Feng Luo, Wei‐Hai Chen, & Xian‐Zheng Zhang. (2021). Recent Advances in Engineered Materials for Immunotherapy‐Involved Combination Cancer Therapy. Advanced Materials. 33(31). e2007630–e2007630. 165 indexed citations
15.
Luo, Guo‐Feng, Yonatan Biniuri, Wei‐Hai Chen, et al.. (2020). Modelling Photosynthesis with ZnII‐Protoporphyrin All‐DNA G‐Quadruplex/Aptamer Scaffolds. Angewandte Chemie. 132(23). 9248–9255. 8 indexed citations
16.
Chen, Wei‐Hai, Guo‐Feng Luo, Wen‐Xiu Qiu, et al.. (2016). Mesoporous silica-based versatile theranostic nanoplatform constructed by layer-by-layer assembly for excellent photodynamic/chemo therapy. Biomaterials. 117. 54–65. 173 indexed citations
17.
Chen, Wei‐Hai, Guo‐Feng Luo, Qi Lei, et al.. (2015). Rational design of multifunctional magnetic mesoporous silica nanoparticle for tumor-targeted magnetic resonance imaging and precise therapy. Biomaterials. 76. 87–101. 123 indexed citations
18.
Chen, Wei‐Hai, Guo‐Feng Luo, Xiao‐Ding Xu, et al.. (2014). Cancer-targeted functional gold nanoparticles for apoptosis induction and real-time imaging based on FRET. Nanoscale. 6(16). 9531–9531. 35 indexed citations
19.
Chen, Wei‐Hai, Xiao‐Ding Xu, Huizhen Jia, et al.. (2013). Therapeutic nanomedicine based on dual-intelligent functionalized gold nanoparticles for cancer imaging and therapy in vivo. Biomaterials. 34(34). 8798–8807. 110 indexed citations
20.
Chen, Wei‐Hai, Xiaoding Xu, Guo‐Feng Luo, et al.. (2013). Dual-Targeting Pro-apoptotic Peptide for Programmed Cancer Cell Death via Specific Mitochondria Damage. Scientific Reports. 3(1). 3468–3468. 92 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026